<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02560805</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00082400</org_study_id>
    <nct_id>NCT02560805</nct_id>
  </id_info>
  <brief_title>Role of Sympathetic Overactivity and Angiotensin II in PTSD and CV</brief_title>
  <acronym>ANG-P</acronym>
  <official_title>Post-Traumatic Stress Disorder and Cardiovascular Disease Risk: Role of Sympathetic Overactivity and Angiotensin II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out why patients with post-traumatic stress disorder
      (PTSD) have an increased risk for heart disease and high blood pressure later in life. A
      second purpose is to find out what causes PTSD patients to have high adrenaline levels during
      stress. This study will also test if a medicine called losartan improves high adrenaline
      levels in patients with PTSD and if a certain gene that has to do with high blood pressure
      might be associated with high adrenaline levels.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle sympathetic nerve activity at rest and during mental stress</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Baroreflex sensitivity (BRS) at rest and during mental stress</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory biomarkers</measure>
    <time_frame>12 weeks</time_frame>
    <description>Inflammatory biomarkers will be assessed using standard assays.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Pressure</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PTSD symptoms</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Stress Disorders, Post-Traumatic</condition>
  <arm_group>
    <arm_group_label>Veterans</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with post-traumatic stress disorder (PTSD) will be evaluated using microneurography, static handgrip exercise, cold pressor test, combat virtual reality video clip, and baroreflex sensitivity using sodium nitroprusside and phenylephrine. For the second phase, they will be randomized to either losartan or atenolol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy controls will be evaluated using microneurography, static handgrip exercise, cold pressor test, combat virtual reality video clip, and baroreflex sensitivity using sodium nitroprusside and phenylephrine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microneurography</intervention_name>
    <description>Skin will be stimulated with a pencil-shaped electrode to find a certain nerve. Once the nerve is found, two tiny sterile wire needles (about the size of acupuncture needles) will be put in the skin. One needle is put just under the skin at a short distance away from the nerve, and the other one into the nerve. The needles are attached to a computer recorder to record the nerve activity. It may take up to one hour to get the needles in the right place. After the tiny needle is in the right place, investigators record nerve activity at rest for about 10 minutes. Then, it will be recorded throughout the rest of the visit (up to 4 hours).</description>
    <arm_group_label>Veterans</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Combat virtual reality video clip</intervention_name>
    <description>Subjects will watch a video clip of combat on a computer screen or wearing video goggles.</description>
    <arm_group_label>Veterans</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Handgrip Exercise</intervention_name>
    <description>Subjects will squeeze a hand dynamometer intermittently.</description>
    <arm_group_label>Veterans</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cold Pressor Test (CPT)</intervention_name>
    <description>Subjects' hand will be submerged in cold water (~0-1°C) up to the wrist for 1 minute.</description>
    <arm_group_label>Veterans</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Nitroprusside (SNP)</intervention_name>
    <description>Subjects will receive sodium nitroprusside 100 µg, which is bolused through an antecubital intravenous catheter.</description>
    <arm_group_label>Veterans</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Nitropress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <description>Subjects will receive phenylephrine 150 µg, which is bolused through an antecubital intravenous catheter 60 seconds after the sodium nitroprusside bolus</description>
    <arm_group_label>Veterans</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Subjects will receive Losartan 25 mg once a day orally up to 12 weeks</description>
    <arm_group_label>Veterans</arm_group_label>
    <other_name>Cozaar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol</intervention_name>
    <description>Subjects will receive Atenolol 25 mg once a day orally up to 12 weeks</description>
    <arm_group_label>Veterans</arm_group_label>
    <other_name>Tenormin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  veterans ages 18-65 years old with PTSD and without PTSD (controls) matched for age,
             gender, and race.

        Exclusion Criteria:

          -  pregnancy

          -  hypertension

          -  diabetes

          -  heart or vascular disease

          -  illicit drug use

          -  excessive alcohol use (&gt;2 drinks per day)

          -  hyperlipidemia

          -  autonomic dysfunction

          -  current treatment with clonidine, beta blockers, angiotensin-converting-enzyme (ACE)
             inhibitors, or angiotensin II receptor blockers (ARBs)

          -  treatment with monoamine oxidase (MAO) inhibitors within the last 14 days

          -  any serious systemic disease

          -  chronic kidney disease defined as estimated glomerular filtration rate (GFR) &lt; 60
             cc/min

          -  hyperkalemia (serum potassium &gt; 5 meq/dL)

          -  systolic blood pressure &lt; 100 mm Hg

          -  diastolic blood pressure &lt; 60 mm Hg

          -  heart rate &lt; 50 beats/min

          -  known hypersensitivity to ARBs or beta blockers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeanie Park, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melanie Jefferson, MS</last_name>
    <phone>404-321-6111</phone>
    <phone_ext>7040</phone_ext>
    <email>melanie.l.jefferson@emory.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Atlanta VA Medical Center</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Kankam, MS</last_name>
      <phone>404-321-6111</phone>
      <phone_ext>7040</phone_ext>
      <email>melanie.l.jefferson@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Jeanie Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2015</study_first_submitted>
  <study_first_submitted_qc>September 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2015</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Jeanie Park</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Atenolol</mesh_term>
    <mesh_term>Nitroprusside</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Angiotensinogen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

